West Paces Advisors’s Novo Nordisk NVO Stock Holding History

West Paces Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.08K	Buy	+85	New	+$3.65K	﹤0.01%	481
2024 Q4	–	Sell	-40	Closed	-$4.76K	–	570
2024 Q3	$4.76K	Sell	40 -300	-88%	-$40K	﹤0.01%	387
2024 Q2	$48.5K	Sell	340 -40	-11%	-$5.3K	0.01%	220
2024 Q1	$48.8K	Hold	380	–	–	0.01%	233
2023 Q4	$39.3K	Buy	380 +80	+27%	+$7.91K	0.01%	246
2023 Q3	$27.3K	Hold	300	–	–	0.01%	270
2023 Q2	$24.3K	Hold	300	–	–	0.01%	288
2023 Q1	$23.9K	Hold	300	–	–	0.01%	288
2022 Q4	$20.3K	Hold	300	–	–	0.01%	290
2022 Q3	$14.9K	Buy	+300	New	+$16.1K	0.01%	304
2017 Q1	–	Sell	-500	Closed	-$8.71K	–	530
2016 Q4	$8.96K	Buy	+500	New	+$9.06K	0.01%	348

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

West Paces Advisors's NVO Position: Q2 2026 in Review

West Paces Advisors opened a new position in Novo Nordisk (NVO) in Q2 2026: 85 shares worth $4.08K. The stake represents ﹤0.01% of the portfolio and ranks #481 among its holdings. This is a return to the name: West Paces Advisors previously reported a position in NVO as recently as Q3 2024.

West Paces Advisors first reported a position in NVO in Q4 2016 and has held it in 11 quarters since. The position peaked at $48.8K in Q1 2024. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

West Paces Advisors held 85 shares of Novo Nordisk worth $4.08K as of Q2 2026.
Novo Nordisk was a new West Paces Advisors position in Q2 2026.
Novo Nordisk made up ﹤0.01% of West Paces Advisors's portfolio in Q2 2026, its #481 holding.
West Paces Advisors first reported a position in Novo Nordisk in Q4 2016 and has held it in 11 quarters since.
West Paces Advisors's Novo Nordisk position peaked at $48.8K in Q1 2024.
1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on West Paces Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.